
New targeted drugs transform HER2, ROS1 and ALK lung cancer care, boosting brain response and survival—while precision choices still matter.

Bruna Pellini, MD, is the chief of Thoracic Medical Oncology at Baptist Health Miami Cancer Institute.

Published: February 10th 2026 | Updated: